FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

6 Observations in Samsung Biologics FDA-483

FDA releases the form FDA-483 with six observations from an inspection at the Samsung Biologics drug manufacturing facility in Incheon, Korea.

Biologics

Fast Track for Glioblastoma Vaccine

FDA grants Diakonos Oncology a fast-track designation for the companys dendritic cell vaccine, DOC1021, for use in patients with glioblastoma multifor...

Human Drugs

Hear Danco Mifeprex SCOTUS Appeal: PhRMA

PhRMA calls on the Supreme Court to hear a Danco Laboratories/FDA appeal of a 5th Circuit Court of Appeals decision restricting use of the abortifacie...

latest-news-card-1
Human Drugs

FDA Denies UCB Generic Fintepla Petition

FDA denies without comment the specific requests in a UCB petition asking the agency to not approve an Apotex ANDA for generic Fintepla unless specifi...

latest-news-card-1
Human Drugs

Omeros Discontinues Narsoplimab Development

Omeros stops the development of narsoplimab for treating immunoglobulin A nephropathy based on Phase 3 clinical trial data that did not show statistic...

latest-news-card-1
Human Drugs

Skyrizi Better Than Stelara: AbbVie Data

AbbVie reports positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of its Skyrizi (risankizumab) comp...

latest-news-card-1
Human Drugs

Guide on Testing Pharmaceutical Alcohols

FDA publishes a final guidance entitled Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol.

latest-news-card-1
Human Drugs

Guidance on Diabetic Foot Infection Drugs

FDA posts a draft guidance entitled Diabetic Foot Infections: Developing Drugs for Treatment.

latest-news-card-1
Federal Register

Zofran Not Withdrawn Over Safety/Efficacy

Federal Register notice: FDA determines that Sandozs Zofran ODT (ondansetron) orally disintegrating tablets (4mg and 8mg) were not withdrawn due to sa...

latest-news-card-1
Human Drugs

Aldeyra Tussles With FDA on NDA Data

Aldeyra Therapeutics says it is addressing substantive late review-cycle concerns raised by FDA on the companys NDA for reproxalap for treating dry ey...